SUMMARY
The medical records of 84 patients with stool cultures positive for Clostridium difficile during the period August 2007 to June 2009 were retrospectively reviewed. A case of confirmed (toxigenic) C. difficile infection (CDI) was defined by the presence of symptoms (fever, diarrhoea, abdominal discomfort or distension, ileus) and the presence of toxigenic C. difficile. Patients with compatible clinical symptoms and stool cultures positive for non-toxigenic C. difficile isolates were defined as probable (non-toxigenic) CDI cases. Of these 84 patients, 50 (59·5%) were diagnosed as confirmed CDI and 34 (40·5%) as probable CDI. Thirteen (15·5%) of the 84 patients died during their hospital stay. Usage of proton pump inhibitors was a significant independent risk factor for CDI (OR 3·21, P = 0·014). Of the 50 isolates associated with confirmed CDI, seven (8·3%) carried binary toxin genes (cdtAB), and six (7·1%) had a deletion in the tcdC gene. The mortality rate in confirmed CDI patients with isolates exhibiting deletion in the tcdC gene (2/6, 33·3%), those with isolates harbouring binary toxin genes (2/7, 28·6%), and those with isolates containing mutations in gyrA (2/7, 28·6%) and gyrB (1/2, 50%) was higher than the overall mortality rate (10/50, 20%) in patients with confirmed CDI.
Key words: Clostridium difficile infection, clinical characteristics, outcome, Taiwan, toxin genes
INTRODUCTION
Clostridium difficile is the most important cause of nosocomial diarrhoea [1, 2]. C. difficile infection (CDI) can range in severity from asymptomatic colonization to severe diarrhoea with pseudomembranous colitis to death. Patients infected with highly virulent strains [polymerase chain reaction (PCR) ribotypes 027 and 078] have severe clinical symptoms and a poor prognosis [1, 2]. Studies have shown that highly virulent strains may have a tendency towards fluoroquinolone resistance and tend to contain genes for toxin A, toxin B, binary toxin, and a deletion in the tcdC gene [1, 3]. Several studies have demonstrated that the role of binary toxin in mediating CDI remains controversial [1, 3].
Few molecular epidemiological studies on the presence of toxic genes of C. difficile isolates in patients with CDI have been conducted in Taiwan. We recently found dissemination of a predominant C. difficile clone in Taiwan. Although some of the isolates (9·9%) contained toxin A/toxin B, binary toxin, and a deletion in the tcdC gene, no isolates of ribotypes 027 or 078 were found [4].
Two recent studies on the prevalence and clinical features of CDI in Taiwan demonstrated that 36·4% of patients with CDI had prolonged diarrhoea and that the recurrence rate was 8·1% in southern Taiwan [5, 6]. In addition, both of those studies showed that the incidence of CDI increased during the study period. Those studies, however, did not investigate the association between the severity and outcome of patients with CDI and the presence of toxin genes (toxin A/toxin B and binary toxin) in the isolates.
PATIENTS AND METHODS
Patients and setting
This retrospective study included 84 inpatients aged ⩾18 years with a positive stool culture for C. difficile during the period August 2007 to December 2009. Positive cultures were obtained from 79 patients at the National Taiwan University Hospital (NTUH), a 2900-bed tertiary-care hospital, and from five inpatients at the National Cheng-Kung University Hospital (NCKUH), a 1600-bed institution. Clinical information including age, gender, the presence of underlying diseases, clinical presentations, use of drugs (antimicrobial agents, steroids, and anti-peptic ulcer agents) within 30 days of onset of symptoms, laboratory data obtained 2 days before or 1 day after diagnosis, and outcome was collected from medical records.
Definitions
Diarrhoea was defined as ⩾3 unformed stools occurring within 24 h [7, 8]. Fever was defined as a body temperature ⩾38 °C. A case of confirmed (toxigenic) CDI was defined by the presence of gastrointestinal symptoms, such as fever, diarrhoea, abdominal discomfort or distension, or ileus, with a stool culture positive for toxigenic C. difficile strains [9]. In our study, patients with compatible clinical symptoms and stool cultures positive for non-toxigenic C. difficile isolates were defined as probable (non-toxigenic) CDI cases. CDI-related mortality was defined as patients with confirmed CDI who died as a consequence of CDI during hospitalization. Invasive disease was defined as patients with blood cultures positive (bacteraemia) for C. difficile.
Bacterial culture for C. difficile
Liquid or semisolid stool samples were inoculated onto cycloserine-cefoxitin-fructose agar (CCFA, BBL Microbiology Systems, USA) [10]. After incubation at 35 °C for 48 h under anaerobic conditions, growth was identified as C. difficile on the basis of Gram staining results (large Gram-positive rods), typical odour, and biochemical characteristics by the Vitek anaerobe identification card (ANI) (bioMérieux Inc., France). Isolates of C. difficile were frozen at −70 °C in brain-heart infusion broth (BBL Microbiology Systems) and 15% glycerol prior to testing.
Microbiological analysis
A multiplex PCR assay was used for the detection of tcdA, tcdB, cdtA, and cdtB, with 16S rDNA as an internal PCR control. All isolates were subjected to tcdC gene sequencing [11]. The gyrA and gyrB genes of the isolates were amplified using the primer couple as described previously [4, 12]. An automated repetitive extragenic palindromic sequence-based PCR (rep-PCR) typing method (DiversiLab; Bacterial Barcodes Inc., USA) was used to determine the DNA fingerprints of the 84 isolates in accordance with the manufacturer's instructions [4, 13]. Similarity of the isolates (rep-PCR types) was determined and interpreted as previously described [4, 13, 14]. PCR ribotypes for isolates of the main rep-PCR types were determined as previously described [13, 15].
Statistical analysis
Clinical characteristics and outcomes of patients with confirmed and probable CDI (two groups) were analysed. The Student's t test was used to compare continuous variables between groups and the results are presented as mean ± standard deviation (s.d.). The χ2 test was used to compare categorical variables between groups. Risk factors with a P value <0·10 in the univariate analyses were included in a multiple logistic regression model to study the association between risk factors for CDI and patients' outcomes. All statistical analyses were performed with the statistical package SPSS for Windows version 12 (SPSS Inc., USA). A P value <0·05 was considered to indicate statistical significance.
RESULTS
Records of 84 patients with positive stool cultures of C. difficile, including 79 patients from the NTUH and five from at the NCKUH, during the period August 2007 to December 2009 were reviewed. All of the patients presented with fever and concurrent gastrointestinal symptoms (diarrhoea, abdominal pain, ileus). Of these 84 patients, 50 (59·5%) were identified as confirmed CDI cases and 34 patients were probable CDI cases.
Of the 84 patients, 63 (75%) had underlying diseases and 13 (15·5%) patients had invasive diseases (bacteraemia). All the stool specimens from the 84 patients were negative for other enteric bacterial pathogens (Salmonella, Shigella, Aeromonas, Plesiomonas, Campylobacter, Vibrio spp.) The most common underlying disease of the 84 patients was haematological malignancy (40·5%, n = 34), followed by endocrine diseases (22·6%, n = 19). Fifty-one (60·7%) patients received antibiotic treatment (range 3 days to 3 months), 49 (58·3%) patients received proton pump inhibitors (PPIs), and 38 (45·2%) patients had a recent history of steroid usage. Fever (40·5%, n = 34) was the most common clinical presentation, followed by abdominal discomfort (20·2%, n = 17). Thirteen patients (15·5%) died during hospitalization. Further analysis revealed that patients who died were more likely than patients who survived to have received PPIs [odds ratio (OR) 9·3, 95% confidence interval (CI) 1·34–64·23, P = 0·024], to have invasive diseases (OR 7·7, 95% CI 1·27–46·35, P = 0·026), to have higher blood urea nitrogen levels (24·6 ± 22·3 vs. 39·42 ± 29·51, P=0·04), and to have higher alanine aminotransferase (ALT) levels (41·98 ± 40·81 vs. 81·29 ± 61·63, P=0·03).
Table 1 compares the clinical and demographic variables between the 50 patients with confirmed CDI and the 34 patients with probable CDI. The two groups of patients were similar with respect to age, sex, underlying diseases, drug exposure, and clinical symptoms. Only PPI usage differed significantly between the two groups of patients (P = 0·02). In addition, logistic regression analysis revealed that exposure to PPIs was a significant independent risk factor for confirmed CDI (OR 3·2, 95% CI 1·26–8·18, P = 0·014). Patients with confirmed CDI had higher levels of C-reactive protein (P = 0·04) (Table 2). The mortality rate did not differ between patients with confirmed CDI (n = 10, 20%) and patients with probable CDI (n = 3, 8·8%, P = 0·35). In addition, although patients who died were more likely than survivors to have been exposed to PPIs, there was no significant difference between the two groups of patients (90% vs. 65%, P=0·24) (Table 1).
Table 1.
Clinical characteristics of 84 patients with positive stool culture for C. difficile based on the presence [patients with confirmed C. difficile infection (CDI)] or absence (patients with probable CDI) of toxin genes of isolates
| Characteristic | Confirmed CDI (toxin gene-positive) (n = 50) | Probable CDI (toxin gene-negative) (n = 34) | P value |
|---|---|---|---|
| Age, years | 59 ± 23 | 58 ± 20 | 0·88 |
| Sex | 0·38 | ||
| Female | 21 (42%) | 18 (52·9%) | |
| Male | 29 (58%) | 16 (47·1%) | |
| Underlying disease | |||
| Any | 37 (74%) | 26 (76·5%) | 1·00 |
| Solid tumour | 9 (18%) | 7 (20·6%) | 0·78 |
| Haematological malignancy | 19 (38%) | 15 (44·1%) | 0·65 |
| Endocrine diseases | 13 (26%) | 6 (17·6%) | 0·43 |
| Cardiovascular diseases | 3 (6%) | 1 (2·9%) | 0·64 |
| Genitourinary diseases | 12 (24%) | 3 (8·8%) | 0·13 |
| Operation | 11 (22%) | 10 (29·4%) | 0·33 |
| Antibiotic therapy | |||
| Any | 29 (58%) | 22 (64·7%) | 0·65 |
| Penicillins | 3 (6%) | 4 (11·8%) | 0·41 |
| Cephalosporins | |||
| Any | 11 (22%) | 9 (26·5%) | 0·57 |
| First generation | 1 (2%) | 3 (8·8%) | 0·29 |
| Second generation | 0 (0%) | 0 (0%) | |
| Third generation | 4 (8%) | 4 (11·8%) | 0·69 |
| Fourth generation | 6 (12%) | 2 (5·9%) | 0·46 |
| Fluoroquinolones | 3 (6%) | 3 (8·8%) | 0·67 |
| Carbapenems | 7 (14%) | 4 (11·8%) | 1·00 |
| Vancomycin | 2 (4%) | 1 (2·9%) | 1·00 |
| Metronidazole | 1 (2%) | 1 (2·9%) | 1·00 |
| Others | 4 (8%) | 0 (0%) | 0·15 |
| Steroid use | 22 (44%) | 16 (47·1%) | 0·82 |
| Anti-peptic ulcer drugs | |||
| Proton pump inhibitor | 35 (70%) | 14 (41·2%) | 0·02 |
| H2 blocker | 4 (8%) | 3 (8·8%) | 1·00 |
| Symptoms | |||
| Fever | 20 (40%) | 14 (41·2%) | 0·90 |
| Abdominal discomfort | 11 (22%) | 6 (17·6%) | 0·84 |
| Invasive diseases (bacteraemia) | 6 (12%) | 7 (20·6%) | 0·36 |
| Overall mortality | 10 (20%) | 3 (8·8%) | 0·35 |
Bold values indicate significant difference (P < 0·05).
Values given are mean ± standard deviation or n (%).
Table 2.
Laboratory findings of 84 patients with positive stool culture for C. difficile based on the presence [patients with confirmed C. difficile infection (CDI)] or absence (patients with probable CDI) of toxin genes of isolates
| Finding | Confirmed CDI (toxin gene-positive) (n = 50) | Probable CDI (toxin gene-negative) (n = 34) | P value |
|---|---|---|---|
| White blood cell (cell/μl) | 8660 ± 6652 | 6543 ± 4930 | 0·1 |
| Haemoglobin (g/dl) | 9·83 ± 1·67 | 9·81 ± 1·63 | 0·95 |
| Neutrophil (%) | 54·61 ± 35·28 | 62·90 ± 26·78 | 0·28 |
| Platelet (cell/μl) | 142660 ± 97511 | 145313 ± 99145 | 0·9 |
| BUN (mg/dl) | 30·51 ± 28·48 | 21·66 ± 13·97 | 0·07 |
| Creatinine (mg/dl) | 1·65 ± 1·77 | 1·09 ± 0·93 | 0·07 |
| Sodium (mequiv/l) | 135·01 ± 7·22 | 137·37 ± 3·98 | 0·08 |
| Potassium (mequiv/l) | 3·84 ± 0·7 | 3·78 ± 0·55 | 0·68 |
| CRP (mg/dl) | 7·61 ± 6·84 | 2·7 ± 2·54 | 0·04 |
| Albumin (mg/dl) | 3·50 ± 0·67 | 3·45 ± 0·67 | 0·83 |
| Bilirubin, total (mg/dl) | 1·48 ± 3·18 | 1·6 ± 2·37 | 0·89 |
| Bilirubin, direct (mg/dl) | 0·81 ± 1·16 | 0·82 ± 0·64 | 0·97 |
| AST (IU/l) | 51·05 ± 89·99 | 40·13 ± 31·63 | 0·52 |
| ALT (IU/l) | 46·94± 43·53 | 46·64 ± 47·94 | 0·98 |
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein.
Values given are mean ± standard deviation.
Bold values indicate significant difference (P < 0·05).
All of the 50 isolates from confirmed CDI patients contained both toxin A and toxin B genes (tcdA/tcdB). Seven (7/84, 8·3%) isolates carried both tcdA/tcdB and binary toxin genes (cdtA/cdtB) and six (6/84, 7·1%) of the seven isolates also possessed a deletion in the tcdC gene. Seven isolates had mutations in the gyrA gene and two isolates had changes in gyrB (Table 3). Only one isolate contained all toxin genes and mutations in both gyrA and gyrB genes (Table 3). None of the isolates belonged to the highly virulent PCR ribotypes 027 or 078.
Table 3.
Genotypic characteristics of 50 C. difficile isolates from patients with confirmed C. difficile infection
| No. of isolates | tcdA/tcdB | cdtA/cdtB | tcdC deletion | Substitution(s) in | |
|---|---|---|---|---|---|
| gyrA | gyrB | ||||
| 36 | +/+ | – | – | – | – |
| 5 | +/+ | + | + | – | – |
| 1 | +/+ | + | – | – | – |
| 6 | +/+ | – | – | Thr82 to Ile | – |
| 1 | +/+ | – | – | – | Ser416 to Ala |
| 1 | +/+ | + | + | Thr82 to Ile | Ser416 to Ala |
There were no significant differences in clinical or laboratory findings between confirmed CDI patients who died (n = 10) and those that survived (n = 40) with the exception of haemoglobin level (P = 0·01). The mortality rate in confirmed CDI patients with isolates exhibiting deletion in the tcdC gene (2/6, 33·3%), those with isolates harbouring binary toxin genes (2/7, 28·6%), and those with isolates containing mutations in gyrA (2/7, 28·6%) and gyrB (1/2, 50%) was higher than the overall mortality rate in patients with confirmed CDI in our study; however, there were no significant differences. There was no significant difference (P = 0·09) in mortality between the patients who had isolates with (n = 6) and without (n = 34) the three genetic characteristics [tcdA/tcdB, binary toxin (cdtA/cdtB) genes and tcdC deletion] (Table 4). However, the differences were significant regarding serum sodium levels (132·3 ± 4·72 vs. 137·4 ± 3·98, P = 0·048), and ALT (10·5 ± 0·71 vs. 48·3 ± 49·66, P = 0·001) and aspartate aminotransferase (AST) (15·33 ± 3·79 vs. 37·93 ± 31·66, P = 0·002) levels between these two groups (Table 4) in the univariate analyses. Further multiple logistic regression analysis did not show significant differences.
Table 4.
Clinical analysis of 40 patients who had isolates with and without the three genetic characteristics [tcdA/tcdB, binary toxin (cdtA/cdtB) genes and tcdC deletion]
| Characteristic | Patients with isolates with tcdA/tcdB, cdtA/cdtB genes and tcdC deletion | P value | |
|---|---|---|---|
| No (n = 34) | Yes (n = 6) | ||
| Male sex | 16 (47·1%) | 2 (33·3%) | 0·53 |
| Any underlying disease | 26 (76·5%) | 5 (83·3%) | 0·71 |
| Death | 3 (8·8%) | 2 (33·3%) | 0·09 |
| Any antibiotic therapy | 22 (64·7%) | 2 (33·3%) | 0·20 |
| Operation | 8 (26. 7%) | 0 (0%) | 0·71 |
| Steroid use | 16 (47·1%) | 2(33·3%) | 0·30 |
| Anti-ulcer drugs | |||
| Proton pump inhibitor | 14 (41·2%) | 2 (33·3%) | 0·45 |
| H2 blocker | 3 (8·8%) | 0 (0%) | 1·00 |
| Symptoms | |||
| Fever | 14 (41·2%) | 2 (33·3%) | 0·54 |
| Abdominal discomfort | 5 (14·7%) | 1 (16. 7%) | 0·59 |
| Invasive diseases (bacteraemia) | 7 (20·6%) | 3 (50%) | 1·00 |
| Laboratory findings | |||
| White blood cell (cell/μl) | 6543 ± 4929·9 | 11073·3 ± 8324·1 | 0·07 |
| Haemoglobin (g/dl) | 9·81 ± 1·63 | 10·68 ± 1·64 | 0·24 |
| Neutrophil (%) | 62·89 ± 26·78 | 62·27 ± 47·86 | 0·97 |
| Platelet (cell/μl) | 145313 ± 99145 | 190667 ± 125371 | 0·33 |
| BUN (mg/dl) | 21·66 ± 13·97 | 54·18 ± 38·92 | 0·10 |
| Creatinine (mg/dl) | 1·09 ± 0·93 | 2·57 ± 2·76 | 0·25 |
| Sodium (mequiv/l) | 137·4 ± 3·98 | 132·3 ± 4·73 | 0·049 |
| Potassium (mequiv/l) | 3·78 ± 0·55 | 3·57 ± 0·40 | 0·53 |
| CRP (mg/dl) | 2·70 ± 2·54 | 12·00 ± 14·66 | 0·39 |
| Albumin (mg/dl) | 3·45 ± 0·67 | 3·2 ± 0·62 | 0·56 |
| Bilirubin-total (mg/dl) | 1·60 ± 2·37 | 0·78 ± 0·24 | 0·13 |
| AST (IU/l) | 37·93 ± 31·66 | 15·33 ± 3·79 | 0·002 |
| ALT (IU/l) | 48·30± 49·66 | 10·50 ± 0·71 | 0·001 |
| Mortality | 3 (8·8%) | 2 (33·3%) | 0·09 |
| tcdA/tcdB, cdtA/cdtB genes and tcdC deletion | |||
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein.
Values given are mean ± standard deviation or n (%).
Bold values indicate significant difference (P < 0·05).
DISCUSSION
All virulent C. difficile strains contain five genes: tcdR, tcdB, tcdE, tcdA, and tcdC. The tcdR and tcdC genes are regulatory genes and the tcdE gene is a porin gene [16]. The tcdA and tcdB genes encode toxins A and B [16]. The tcdC gene is a negative regulator of the two major toxins. Defects in this gene may result in toxin over-expression [17, 18]. In addition to toxins A and B, highly virulent strains (ribotypes 027 and 078) tend to produce a third toxin (binary toxin). It is encoded by the genes cdtA and cdtB [19]. It is proposed that binary toxin has an additive effect with toxins A and B, thereby adding to the virulence of those strains [20].
Another characteristic of the highly virulent strains of C. difficile is their common resistance to fluoroquinolones [12]. Resistance to that class of antimicrobial agents has been shown to be associated with mutations in the gyrA and gyrB genes [12]. In addition, CDI due to highly virulent strains is associated with high morbidity and mortality rates. In this study, all the eight isolates exhibiting either gyrA (n = 6), gyrB (n = 1), or gyrA and gyrB (n = 1) genes were all resistant to moxifloxacin (minimum inhibitory concentration ⩾4 μg/ml) [4]. However, we found no significant differences in mortality between patients with confirmed CDI and patients with probable CDI. A possible explanation for that finding is that our study populations were relatively small and that none of the patients had confirmed CDI due to highly virulent, NAP1 (ribotype 027)- or NAP8 (ribotype 078)-containing strains.
The risk factors for CDI include advanced patient age, hospitalization, gastrointestinal surgery, chemotherapy, and exposure to antimicrobial agents [9]. Another potential, although controversial, risk factor is the use of acid-suppressing medications, such as histamine-2 (H2) blockers and PPIs. In this study, we found that the rate of PPI usage was higher in patients with confirmed CDI. Some researchers have suggested that this association is the result of confounding factors such as underlying severity of illness and duration of hospital stay [2, 21, 22]. Interestingly, some studies have shown that patients with community-associated CDI are more likely to have received PPIs than patients that did not [23, 24], and that PPI usage is a risk factor for the development of CDI [25–27]. Paredes-Sabja et al. reported that reduction in gastric acid secretion might allow C. difficile to be ingested and that elevated pH levels (pH 6, determined to be optimal) might favour spore germination [28]. If acid suppression were in fact the true cause of CDI in patients receiving PPIs, then H2 blockers should also be associated with the development of CDI. In our study, however, H2 blockers were not associated with infections due to C difficile. A possible reason for that finding is that PPI therapy is a more potent inhibitor of gastric acid than H2 blockers, thereby increasing the intragastric pH. In a large pharmacoepidemiological cohort study, the occurrence of nosocomial CDI was 0·3% in patients receiving no acid suppression, 0·6% in those receiving H2 blockers, and 0·9–1·4% in patients receiving PPI therapy. A dose–response effect was found after adjustments for risk factors such as age, comorbid conditions, and antibiotic exposure. The odds ratio rose from 1·5 (H2 blocker), to 1·7 (daily PPI), to 2·4 (daily PPI) [29].
The mortality rate in patients with confirmed CDI in our study (20%) was similar to that of the crude mortality rate (23·5–24·8%) in other studies on patients with CDI [2, 5]. PPI usage by CDI patients contributed to a higher mortality rate than for those without PPI usage although the difference was not significant. PPI therapy is associated with a number of adverse reactions including increased susceptibility to bone fractures, infections (e.g. pneumonia, enteric infections, small intestinal bacterial overgrowth, spontaneous bacterial peritonitis), and altered gastric function (e.g. enteric malabsorption of vitamins and minerals, hypergastrinaemia-related neoplasia, impaired gastric emptying of solids) [18, 20]. All of those adverse reactions are associated with higher mortality for hospitalized patients. Mortality of hospitalized patients is also associated with the severity of underlying illness. In the present study, we found that bacteraemia due to C. difficile was associated with a higher mortality rate.
Our study has several limitations. First, the real incidence of CDI at the hospitals was difficult to define because detection of toxins and toxin genes was not routinely performed for stool specimens of all patients with clinically suspected CDI. This might have resulted in bias in our findings. Second, we only screened toxin genes and PCR ribotyping of hypervirulent strains (ribotypes 027 and 078). Certain ribotypes with special characteristics might have been missed. Third, the PPI concentration and dosage were not investigated in this study. Although we found PPI usage to be a risk factor for the development of CDI, we were unable to evaluate whether there was a dose–response effect of PPIs.
In conclusion, we found no association between the presence of any toxin gene and the severity of CDI. Our data, however, demonstrated that PPI usage was associated with a higher risk of CDI. PPIs, therefore, should be administered with caution in patients with known risk factors for CDI, including patients of advanced age, those who have undergone gastrointestinal surgery, and patients that have been exposed to antimicrobial agents.
DECLARATION OF INTEREST
None.
REFERENCES
- 1.Goorhuis A, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clinical Infectious Diseases 2008; 47: 1162–1170. [DOI] [PubMed] [Google Scholar]
- 2.Loo VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. New England Journal of Medicine 2005; 353: 2442–2449. [DOI] [PubMed] [Google Scholar]
- 3.Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079–1084. [DOI] [PubMed] [Google Scholar]
- 4.Lin YC, et al. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. Antimicrobial Agents and Chemotherapy 2011; 55: 1701–1705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Chung CH, et al. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. Journal of Microbiology Immunolology and Infection 2010; 43: 119–125. [DOI] [PubMed] [Google Scholar]
- 6.Hsu MS, et al. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan. Journal of Microbiology Immunolology and Infection 2006; 39: 242–248. [PubMed] [Google Scholar]
- 7.McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. Journal of Infectious Diseases 1990; 162: 678–684. [DOI] [PubMed] [Google Scholar]
- 8.McFarland LV, et al. Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 1989; 320: 204–210. [DOI] [PubMed] [Google Scholar]
- 9.Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology 2010; 31: 431–455. [DOI] [PubMed] [Google Scholar]
- 10.Baron EJ, et al. Classification and identification of bacteria, In Murray PR, Baron EJ, Pfaller MA, et al. , eds. Manual of Clinical Microbiology, 6th edn. ASM Press, Washington, DC, 1995, pp. 249–264. [Google Scholar]
- 11.Persson S, Torpdahl M, Olsen KE. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clinical Microbiology and Infection 2008; 14: 1057–1064. [DOI] [PubMed] [Google Scholar]
- 12.Dridi L, et al. gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrobial Agents and Chemotherapy 2002; 46: 3418–3421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Pasanen T, et al. Comparison of repetitive extragenic palindromic sequence-based PCR with PCR ribotyping and pulsed-field gel electrophoresis in studying the clonality of Clostridium difficile. Clinical Microbiology and Infection 2011; 17: 166–175. [DOI] [PubMed] [Google Scholar]
- 14.Lee NY, et al. Clostridium difficile bacteremia, Taiwan. Emerging Infectious Diseases 2010; 16: 1204–1210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Stubbs SL, et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. Journal of Clinical Microbiology 1999; 37: 461–463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Hundsberger T, et al. Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. European Journal of Biochemistry 1997; 244: 735–742. [DOI] [PubMed] [Google Scholar]
- 17.Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Molecular Microbiology 2007; 64: 1274–1288. [DOI] [PubMed] [Google Scholar]
- 18.Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115–1127. [DOI] [PubMed] [Google Scholar]
- 19.McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New England Journal of Medicine 2005; 353: 2433–2441. [DOI] [PubMed] [Google Scholar]
- 20.McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Current Opinion of Gastroenterology 2010; 26: 624–631. [DOI] [PubMed] [Google Scholar]
- 21.Pepin J, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clinical Infectious Diseases 2005; 40: 1591–1597. [DOI] [PubMed] [Google Scholar]
- 22.Shah S, et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. Quarteryly Journal of Medicine 2000; 93: 175–181. [DOI] [PubMed] [Google Scholar]
- 23.Dial S, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. Journal of American Medical Association 2005; 294: 2989–2995. [DOI] [PubMed] [Google Scholar]
- 24.Dial S, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. Canadian Medical Association Journal 2006; 175: 745–748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Cunningham R, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. Journal of Hospital Infection 2003; 54: 243–245. [DOI] [PubMed] [Google Scholar]
- 26.Kazakova SV, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Archives of Internal Medicine 2006; 166: 2518–2524. [DOI] [PubMed] [Google Scholar]
- 27.Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. American Journal of Gastroenterology 2007; 102: 2047–2056. [DOI] [PubMed] [Google Scholar]
- 28.Paredes-Sabja D, et al. Germination of spores of Clostridium difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD). Microbiology 2008; 154: 2241–2250. [DOI] [PubMed] [Google Scholar]
- 29.Howell MD, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Archives of Internal Medicine 2010; 170: 784–790. [DOI] [PubMed] [Google Scholar]